https://www.pharmaradar360.com/article/66a6c858155ca3f1PharmaRadar360en2026-04-06T16:00:00.000ZSector tariff now more than a threat – for some Rx companieshttps://www.pharmaradar360.com/article/42c4b81b3da7cfc4PharmaRadar360en2026-04-06T12:30:00.000ZAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)https://www.pharmaradar360.com/article/e484886095722acfPharmaRadar360en2026-04-06T11:22:39.000ZCRC Confessionals: The Support I Never Dreamed I Could Havehttps://www.pharmaradar360.com/article/7074f789f4de90acPharmaRadar360en2026-04-06T10:00:00.000ZQ&A: Ezekiel Emanuel's simple ruleshttps://www.pharmaradar360.com/article/c271c85c99a8aacfPharmaRadar360en2026-04-06T10:00:00.000ZBP-lowering drugs reduced major CV events to a similar extent in patients with or without isolated diastolic hypertensionhttps://www.pharmaradar360.com/article/d9970b0b192fe5daPharmaRadar360en2026-04-06T10:00:00.000ZMultisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Riskhttps://www.pharmaradar360.com/article/93bbe851b1650fe9PharmaRadar360en2026-04-06T10:00:00.000ZIn MINOCA, stratified treatment guided by MINOCA cause vs. standard care improved angina status at 1 yhttps://www.pharmaradar360.com/article/82783288304f34d2PharmaRadar360en2026-04-06T10:00:00.000ZIn sepsis, a tailored precision immunotherapy strategy improved organ function at 9 dhttps://www.pharmaradar360.com/article/e45eb2db573d26a5PharmaRadar360en2026-04-06T10:00:00.000ZIn patients with painful diabetic neuropathy, pregabalin does not differ from duloxetine for painhttps://www.pharmaradar360.com/article/2c95777c33ffb0eePharmaRadar360en2026-04-06T10:00:00.000ZIn the ED, the Wells score plus age-adjusted D-dimer score ruled out DVT with a failure rate ≤0.8% at 3 mohttps://www.pharmaradar360.com/article/9cdd94ddd1bb7439PharmaRadar360en2026-04-06T10:00:00.000ZIn patients with chronic lung disease, 4 existing PE diagnostic strategies were assessedhttps://www.pharmaradar360.com/article/6807ef8f4979cffcPharmaRadar360en2026-04-06T10:00:00.000ZIn adults with ADHD, atomoxetine, methylphenidate, and CBT reduce symptom severity and the drugs are less tolerable vs. control at 12 wkhttps://www.pharmaradar360.com/article/2b893a96c18aa5fePharmaRadar360en2026-04-06T10:00:00.000ZSummary for Patients: Multisite External Validation of a Clinical Screening Tool for Interpersonal Firearm Violence Riskhttps://www.pharmaradar360.com/article/4c5fee3683d9b899PharmaRadar360en2026-04-06T10:00:00.000ZAfter ischemic stroke in patients receiving aspirin, switching to another antithrombotic regimen does not reduce recurrencehttps://www.pharmaradar360.com/article/2e8d454bdd5733f5PharmaRadar360en2026-04-06T10:00:00.000ZFirst-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemiahttps://www.pharmaradar360.com/article/0f87363c441fcc9dPharmaRadar360en2026-04-06T10:00:00.000ZThe ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseaseshttps://www.pharmaradar360.com/article/9ac536cdc2e78e72PharmaRadar360en2026-04-06T10:00:00.000ZPlatelet Drp1 phosphorylation provides a platform for immune-based platelet function testinghttps://www.pharmaradar360.com/article/30fed1b03cacf439PharmaRadar360en2026-04-06T06:30:00.000Z大阪大学免疫学フロンティア研究センターとの共同研究による免疫性血小板減少症に関する研究成果がBlood誌に掲載https://www.pharmaradar360.com/article/30de1058add9bb79PharmaRadar360en2026-04-06T06:30:00.000ZResearch Results on Immune Thrombocytopenia from a Joint Study with Osaka University’s IFReC Published in Bloodhttps://www.pharmaradar360.com/article/4bdde72027b7c6d4PharmaRadar360en2026-04-06T03:00:00.000Z[SHINSA]List of Approved Drugs: April 2004 to September 2025https://www.pharmaradar360.com/article/d751e33aa5c6e59dPharmaRadar360en2026-04-06T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/3f4eae7978d5bfb6PharmaRadar360en2026-04-06T02:45:00.000ZRelics of an ancient sandstorm on Mars point to Earth-like windshttps://www.pharmaradar360.com/article/cf0828014bcbe377PharmaRadar360en2026-04-06T00:00:00.000Zask our experts monoclonal antibodies explainedhttps://www.pharmaradar360.com/article/79ee3901e2a4fee7PharmaRadar360en2026-04-06T00:00:00.000Z2026.04.06æ ªä¸»ç ä¼šã®Q&Aã‚’å ¬é–‹ã—ã¾ã—ãŸhttps://www.pharmaradar360.com/article/c6b1bc43b22858d6PharmaRadar360en2026-04-06T00:00:00.000ZPharma Research & Developmenthttps://www.pharmaradar360.com/article/0895c1e9fecacc34PharmaRadar360en2026-04-06T00:00:00.000ZIR and Shareholder Contactshttps://www.pharmaradar360.com/article/b78a2ac9734a36b8PharmaRadar360en2026-04-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/7b0a5c2670715840PharmaRadar360en2026-04-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/385db0a54dababe5PharmaRadar360en2026-04-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/832f3b3887ffde11PharmaRadar360en2026-04-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/3b9fcb540bd09324PharmaRadar360en2026-04-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/fc42954948a76d40PharmaRadar360en2026-04-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/8e00537609db47c9PharmaRadar360en2026-04-06T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/cac0130b1a4d7be0PharmaRadar360en2026-04-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/d7dc927002a017bfPharmaRadar360en2026-04-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/be9f17fc8a6d684dPharmaRadar360en2026-04-06T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/e0c28c2be852c373PharmaRadar360en2026-04-06T00:00:00.000Znews releases enhttps://www.pharmaradar360.com/article/5433b8d829b55333PharmaRadar360en2026-04-06T00:00:00.000ZAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASEhttps://www.pharmaradar360.com/article/bde28323945e285fPharmaRadar360en2026-04-06T00:00:00.000ZIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancerhttps://www.pharmaradar360.com/article/42b2575f78efa978PharmaRadar360en2026-04-06T00:00:00.000Z4/6/2026Press ReleaseAgios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETRead Morehttps://www.pharmaradar360.com/article/1b1c7e5efb70fc20PharmaRadar360en2026-04-05T10:00:00.000ZCanada's Yukon Territory publishes First Nations Cancer Strategyhttps://www.pharmaradar360.com/article/d8187cc118017b58PharmaRadar360en2026-04-05T10:00:00.000ZEuropean Breast Cancer Conference 2026https://www.pharmaradar360.com/article/506822d28e2781b2PharmaRadar360en2026-04-05T10:00:00.000ZSenators demand explanation for US Preventive Services Task Force halthttps://www.pharmaradar360.com/article/7ef24f444f46746dPharmaRadar360en2026-04-05T10:00:00.000ZImmunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trialhttps://www.pharmaradar360.com/article/5083415b7063a3bePharmaRadar360en2026-04-05T10:00:00.000ZConcerns regarding study of spatial emanators for malaria controlhttps://www.pharmaradar360.com/article/bd943948e0165de7PharmaRadar360en2026-04-05T10:00:00.000ZConcerns regarding study of spatial emanators for malaria control - Authors' replyhttps://www.pharmaradar360.com/article/e036b1d00f0571a9PharmaRadar360en2026-04-05T10:00:00.000ZPercutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trialhttps://www.pharmaradar360.com/article/156c478873cbcb24PharmaRadar360en2026-04-05T10:00:00.000ZGlobal burden of cancer in children and adolescents aged 0-19 years, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023https://www.pharmaradar360.com/article/5bc76b8ca9b011bcPharmaRadar360en2026-04-05T10:00:00.000ZPerioperative immunotherapy for resectable hepatocellular carcinoma - Authors' replyhttps://www.pharmaradar360.com/article/76ba1b1da533be73PharmaRadar360en2026-04-05T10:00:00.000ZPerioperative immunotherapy for resectable hepatocellular carcinomahttps://www.pharmaradar360.com/article/5a83e25824b59a2ePharmaRadar360en2026-04-05T10:00:00.000ZClinical phenotyping improves choices of biologics in asthma - Authors' replyhttps://www.pharmaradar360.com/article/056e99717e3a9c40PharmaRadar360en2026-04-05T10:00:00.000ZClinical phenotyping improves choices of biologics in asthmahttps://www.pharmaradar360.com/article/cc25ed6e5611191ePharmaRadar360en2026-04-05T10:00:00.000ZOffline: The scandal of missing mothershttps://www.pharmaradar360.com/article/93ce66bb81f539f7PharmaRadar360en2026-04-05T10:00:00.000ZChildhood cancer: an equity test for global healthhttps://www.pharmaradar360.com/article/aa76381f603ecf0aPharmaRadar360en2026-04-05T10:00:00.000ZChildhood cancer: progress, but not enough